Articles tagged "Liver"

2019 American Transplant Congress
Improved Transplant Outcomes in Ischemia-Free Liver Transplantation: A Report of the First 30 Cases
X. He, Z. Guo, W. Ju, Q. Zhao, S. Huang, J. Yang, L. Wang, Y. Tang, Z. Zhang, Z. Zhu, L. Yang, Y. Zhu, F. Gong, C. Cai, W. Huang, G. Chen, M. Chen, F. Ji, M. Han, A. Hu, L. Wu, Y. Ma, D. Wang, J. Huang, X. Li
Organ Transplant Center, the First Affiliated Hospital of SYSU, Guangzhou, China
*Purpose: We developed a novel procedure called ischemia-free liver transplantation (IFLT) to bridge liver grafts from donors to recipients without cessation of blood supply. Herein,…
2019 American Transplant Congress
Tubastatin-A, an HDAC6 Inhibitor, is Protective in Liver Ischemia Reperfusion Injury and Acetaminophen-Mediated Liver Injury
S. Concors¹, D. Murken¹, P. Hernandez¹, D. Aufhauser¹, Z. Wang¹, G. Ge¹, L. Krumeich¹, T. Bhatti², A. Kozikowski³, W. Hancock², M. H. Levine¹
¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Starwise Therapeutics, Madison, WI
*Purpose: Ischemia reperfusion injury (IRI) causes morbidity and contributes to early graft loss in liver transplantation and no current therapy exists. Liver injury complicates other…
2019 American Transplant Congress
Treatment of Cardiovascular Risk Factors Improves Long Term Outcome Post Liver Transplantation
S. Alghamdi, O. Altayar, T. Zhu, A. Bayudan, J. Fleckenstein, M. Lisker-Melman, J. Crippin, A. Flores
Washington University in St Louis, Saint Louis, MO
*Purpose: Cardiovascular (CV) disease is a leading cause of mortality 1 year after liver transplantation (LT). We aimed to assess the effect of treating CV…
2019 American Transplant Congress
Ex-vivo Xenoperfusion Of Wild Type And Galtko.hcd55 Pig Livers With Human Whole Blood
D. Detelich, C. Rickert, C. Eymard, C. Carroll, S. Kimura, H. Yeh, J. Markmann
Massachusetts General Hospital, Boston, MA
*Purpose: Pig-to-human liver xenotransplantation is not currently feasible due to rapid and profound thrombocytopenia, coagulopathy and hyperacute rejection. Successful development of genetically modified swine to…
2019 American Transplant Congress
Inflammation and Fibrosis Are Observed in 34% of Clinically Stable Adult Liver Transplant Recipients
L. Sun¹, J. Levitsky², S. Feng³, A. Humar⁴, A. J. Demetris⁴, J. Emond⁵, A. Shaked⁶, G. Klintmalm⁷, K. Mason⁸, M. DesMarais¹, A. Priore⁹, N. Bridges⁹, B. E. Burrell¹⁰, S. Chandran³, J. Markmann¹¹
¹ITN, San Francisco, CA, ²Northwestern, Chicago, IL, ³UCSF, San Francisco, CA, ⁴UPMC, Pittsburg, PA, ⁵Columbia, New York, NY, ⁶UPenn, Philadelphia, PA, ⁷Baylor, Dallas, TX, ⁸Rho, Chapel Hill, NC, ⁹NIAID, Bethesda, MD, ¹⁰ITN, Bethesda, MD, ¹¹MGH, Boston, MA
*Purpose: OPTIMAL is a 7-center immunosuppression withdrawal (ISW) study in non-autoimmune, non-HCV adult liver transplant recipients ≥3 yrs post-transplant (tx) (NCT02533180). Subjects underwent a screening…
2019 American Transplant Congress
Ready for Prime Time: Intentional Allocation of Hepatitis C Positive Livers into Hepatitis C Negative Recipients
P. N. Martins¹, B. Movahedi¹, D. Devuni², P. Mahboub¹, A. Bozorgzadeh¹
¹Surgery, Division of Transplantation, University of Massachusets, Worcester, MA, ²Medicine, Division of Hepatology, University of Massachusets, Worcester, MA
*Purpose: The current discrepancy between supply and demand of liver grafts has dramatically increased the waiting time and mortality on the waiting list. The recent…
2019 American Transplant Congress
Kupffer Cells Are Critical for Inflammation Resolution in Liver Ischemia Reperfusion Injury via TIM-4 Mediated Efferocytosis
M. Ni¹, H. Wang¹, D. Jin¹, J. Zhang¹, R. Busuttil¹, J. Kupiec-Weglinski¹, X. Wang², Y. Zhai¹
¹Dumont-UCLA Transplant Center, Los Angeles, CA, ²The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
*Purpose: Liver ischemia reperfusion injury (IRI) remains a clinical problem associated with both surgical and non-surgical settings. Innate immune-dominated inflammation drives the pathogenesis of liver…
2019 American Transplant Congress
Perioperative Lactate Levels Are Sensitive Marker to Predict Early Allograft Dysfunction and Short-Term Graft Failure after Liver Transplant
K. Takahashi¹, S. Nagai², K. Collins², M. Rizzari², M. Safwan², S. Jafri³, T. Oda¹, A. Yoshida², M. Abouljoud²
¹Surgery, University of Tsukuba, Tsukuba, Japan, ²Surgery, Henry Ford Hospital, Detroit, MI, ³Gastroenterology, Henry Ford Hospital, Detroit, MI
*Purpose: Lactate is one of the most frequently used makers to understand real-time graft function after liver transplant (LT). This study aimed to investigate risk…
2019 American Transplant Congress
Tumor Necrosis as a Result to Pre-Transplant Bridging Treatment for Hepatocellular Carcinoma and Its Effect on Post-Transplant Outcome
S. Radunz¹, A. Kirschner¹, J. M. Theysohn², C. Schotten³, T. Benkö¹
¹General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany, ²Diagnostic and Interventional Radiology and Neurradiology, University Hospital Essen, Essen, Germany, ³Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany
*Purpose: As a bridge to liver transplantation, locoregional treatments are commonly employed in hepatocellular carcinoma (HCC) patients to prevent tumor progression during waiting time. Objective…
2019 American Transplant Congress
Restrictive Medicaid Policies Reduce Access to Liver Transplant for Alcohol-Associated Liver Disease
B. P. Lee, V. Eric, P. Mark, J. Dodge, N. Terrault
UCSF, SF, CA
*Purpose: Medicaid policies requiring specific documentation of abstinence (e.g. 6 months) and/or rehabilitation for financial coverage of liver transplant (LT) for alcohol-associated liver disease (ALD)…